Skin-tone bias in pulse oximetry for mission-driven organizations

Decision-ready map

• Program goal: reduce preventable hypoxemia harm

• Risk: missed low oxygen can be more likely in some groups

• Levers: procurement specs + training + escalation pathways

• Audit: monitor outcomes and complaints by subgroup

(1) What it is

Mission-driven programs deploy pulse oximeters for community triage, home monitoring, and outreach because they are portable and inexpensive. Evidence shows some devices can overestimate oxygen saturation in people with darker skin tones, which can miss hypoxemia and worsen inequities when programs use rigid SpO₂ thresholds.

(2) Who it helps

This brief supports organizations that purchase and distribute oximeters, train community health workers, publish guidance, or fund deployments—especially in diverse populations and low-resource settings.

(3) What evidence exists

Large paired studies show higher occult hypoxemia prevalence in Black patients compared with White patients at similar SpO₂. Health-system studies show reproducibility and association with outcomes. A 2024 systematic review finds overestimation in darker skin tones is commonly reported. FDA communications highlight the need for improved evaluation and labeling across skin tones.

(4) Translation barriers

Commodity procurement often lacks stratified validation evidence. Training may not emphasize limitations and mismatch rules. Field conditions (cold extremities, motion) amplify errors. Programs often lack incident reporting systems, so disparities stay invisible.

(5) Equity/safety checks

Procure devices with transparent stratified evidence and clear labeling. Train staff using a simple rule: symptoms override numbers; if in doubt, repeat and refer. Establish escalation pathways and referral criteria that do not depend on one threshold alone. Implement audit and incident reporting with subgroup fields (as appropriate and ethical).

(6) Decision questions

• What decisions depend on SpO₂ thresholds, and what is the harm if hypoxemia is missed?

• Can vendors provide stratified performance evidence and device identification?

• Do SOPs define what to do when symptoms and SpO₂ disagree?

• Do we have monitoring metrics that allow equity auditing?

(7) Practical next steps

1) Add procurement requirements: device model transparency, stratified validation evidence, and labeling.

2) Create a one-page SOP for measurement technique, repeat triggers, and referral.

3) Implement incident reporting and quarterly review stratified by relevant demographics.

4) Publish transparency: why the device was selected and what limitations exist.

(8) References

https://doi.org/10.1056/NEJMc2029240
https://doi.org/10.1016/j.bja.2024.01.023
https://www.fda.gov/media/175828/download
https://www.fda.gov/news-events/press-announcements/fda-proposes-updated-recommendations-help-improve-performance-pulse-oximeters-across-skin-tones